Vejle Sygehus

Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer—The Copenhagen Lung Cancer Risk Model (CPH-Lung)

Purpose Lung cancer screening reduces lung cancer mortality, but identifying high-risk individuals remains difficult. We wanted to develop a blood test–based risk model (CPH-Lung) to improve risk stratification before image-based screening. Materials and Methods We included indiv...

Operationalizing fear of cancer recurrence care: a modified Delphi study establishing a consensus-based clinical pathway for Danish cancer survivors

BACKGROUND AND PURPOSE: Fear of cancer recurrence (FCR) is a prevalent concern among cancer survivors. Although evidence-based FCR guidelines exist, their implementation requires further operationalization. This study aimed to establish expert consensus on a clinical pathway to o...

Constrained distributed heterogeneous two-facility location problems with max-variant cost

This paper studies the design of strategyproof distributed mechanisms for a constrained location problem involving two heterogeneous facilities under the max-variant cost model. A set of agents with private locations on the real line is partitioned into disjoint groups, and the t...

A Scoring System Contributing to the Detection of Radiation Pneumonitis in Elderly Patients with Lung Cancer—Results of the POLCAR Trial

Background/Objectives: A symptom-based scoring system (0–9 points) for the identification of radiation pneumonitis was previously evaluated in lung cancer patients without age restrictions. A threshold of five points appeared optimal to detect pneumonitis. Since elderly patients...

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...

Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

BACKGROUND: Hot flashes are common and often debilitating side effects of castration therapy; a cornerstone in the treatment of metastatic prostate cancer (PCa) as well as in localized or locally advanced PCa when combined with radiotherapy. The evidence for relieving vasomotor s...